Spero Therapeutics, Inc.
(NASDAQ : SPRO)

( )
SPRO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Co.
0.81%59.961.4%$1550.16m
JNJJohnson & Johnson
0.56%140.340.7%$880.30m
PFEPfizer Inc.
0.71%38.300.9%$769.20m
MRKMerck & Co., Inc.
0.10%88.840.7%$670.35m
ABBVAbbVie, Inc.
0.32%87.002.3%$649.82m
LLYEli Lilly & Co.
-0.14%119.601.1%$340.88m
AZNAstraZeneca Plc
0.13%47.681.2%$136.29m
RETAReata Pharmaceuticals, Inc.
-0.12%199.323.5%$133.57m
GSKGlaxoSmithKline Plc
0.66%45.510.2%$128.61m
NVSNovartis AG
0.34%91.950.2%$128.17m
KRTXKaruna Therapeutics, Inc.
3.35%67.630.0%$101.66m
NVONovo Nordisk A/S
-0.59%56.740.1%$92.77m
SNYSanofi
-0.11%46.030.2%$69.98m
ALLKAllakos, Inc.
-4.63%117.360.0%$64.39m
BHVNBiohaven Pharmaceutical Holding Co. Ltd.
2.05%54.860.0%$38.47m

Company Profile

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.